Sep 12, 2022

EvolutTM Transcatheter Aortic Valve Implantation

 
Jan 11, 2021
Medtronic Evolut™ Tavi Now Licensed for Both Bicuspid Aortic Valves at Intermediate or Greater Risk and for Low Risk of Surgical Mortality

BRAMPTON, Ontario – January 11, 2021 - Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE:MDT) ― the world's largest medical technology, services, and solutions company ― has received...
 
Jul 19, 2022
Increasing Access to Improved Patient Outcomes with the Latest Innovation in TAVI

We may reach retirement, but our hearts don’t get a break. In fact once we reach 65, approximately 20 percent of us will experience aortic stenosis, a hardening or narrowing of the aortic...
 

EvolutTM Transcatheter Aortic Valve Implantation (TAVI, also known as TAVR) system is a minimally invasive surgical platform indicated for aortic stenosis for all surgical risk categories in...

EvolutTM Transcatheter Aortic Valve Implantation (TAVI, also known as TAVR) system is a minimally invasive surgical platform indicated for aortic stenosis for all surgical risk categories in Canada. TAVI has a significantly shorter recovery period, and higher patient satisfaction scores than traditional open chest surgery.